Who are Antifibrinolytic treatment's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trasylol, Cyklokapron, Amicar, Tranexamic Acid (TXA), Tranexamic acid + Standard of Care, aprotonin; epsilon aminocaproic acid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/antifibrinolytic-treatment.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Antifibrinolytic treatment — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Antifibrinolytic treatment (Antifibrinolytic treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifibrinolytic. Area: Oncology.

phase 2 Antifibrinolytic Plasminogen activators and plasmin Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Antifibrinolytic treatment (Antifibrinolytic treatment) — Bayer. Antifibrinolytic agents inhibit plasminogen activators and plasmin.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Antifibrinolytic treatment TARGET	Antifibrinolytic treatment	Bayer	phase 2	Antifibrinolytic	Plasminogen activators and plasmin
Trasylol	APROTININ	Bayer	marketed	Antifibrinolytic Agent	Plasminogen	1993-01-01
Cyklokapron	TRANEXAMIC ACID	Exela Pharma	marketed	Antifibrinolytic Agent [EPC]	Plasminogen	1986-01-01
Amicar	AMINOCAPROIC ACID	Epic Pharma Llc	marketed	Antifibrinolytic Agent [EPC]	Plasminogen	1964-01-01
Tranexamic Acid (TXA)	Tranexamic Acid (TXA)	NYU Langone Health	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic acid + Standard of Care	Tranexamic acid + Standard of Care	Pfizer	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
aprotonin; epsilon aminocaproic acid	aprotonin; epsilon aminocaproic acid	University of Rochester	marketed	Antifibrinolytic agent	Plasmin, kallikrein, plasminogen activators

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifibrinolytic class)

Ain Shams University · 1 drug in this class
Bayer · 1 drug in this class
German Heart Center · 1 drug in this class
Institut Kassab d'Orthopédie · 1 drug in this class
Miller Orthopedic Specialists · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Antifibrinolytic treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/antifibrinolytic-treatment. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab